Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)
Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found